Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Feng Chi Biotech's share price for the quarter that ended in Dec. 2025 was NT$17.8. Feng Chi Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 15.4 Mil. Therefore, Feng Chi Biotech's market cap for the quarter that ended in Dec. 2025 was NT$274.1 Mil.
Feng Chi Biotech's quarterly market cap
increased
from Dec. 2024 (NT$304.9 Mil) to Jun. 2025 (NT$314.9 Mil) but then
declined
from Jun. 2025 (NT$314.9 Mil) to Dec. 2025 (NT$274.1 Mil).
Feng Chi Biotech's annual market cap
declined
from Dec. 2023 (NT$353.4 Mil) to Dec. 2024 (NT$304.9 Mil) and
declined
from Dec. 2024 (NT$304.9 Mil) to Dec. 2025 (NT$274.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Feng Chi Biotech's Enterprise Value for Today is NT$63.2 Mil.
Feng Chi Biotech (ROCO:6744) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Feng Chi Biotech Market Cap Related Terms
Feng Chi Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Feng Chi Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6744 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Feng Chi Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feng Chi Biotech Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Feng Chi Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Feng Chi Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feng Chi Biotech (ROCO:6744) has a Market Cap of NT$236.4 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Feng Chi Biotech and its competitors. According to the industry distribution chart, Feng Chi Biotech ranks #1253 out of 1426 companies in the Biotechnology industry, placing it in the top 87.9%.
Is Feng Chi Biotech's Market Cap too high?
Feng Chi Biotech's current Market Cap is NT$236.4 Mil. Based on the distribution chart, Feng Chi Biotech ranks #1253 out of 1426 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Feng Chi Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Feng Chi Biotech ranks #1253 out of 1426 companies for Market Cap. This places Feng Chi Biotech in the lower half of its industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Feng Chi Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Feng Chi Biotech's current Market Cap is NT$236.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.84, compared to a current price of NT$15.35 — trading 26.3% below its estimated fair value. The current Market Cap is NT$236.4 Mil. Feng Chi Biotech's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current Market Cap is NT$236.4 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?
Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued.
The current stock price of NT$15.35 is trading 26.3% below its estimated GF Value™ of NT$20.84.
GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6744:
Market Cap: NT$236.4 Mil
GF Value™: NT$20.84 vs. price of NT$15.35 (26.3% below fair value)
No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
82GF Score
Get the complete analysis for ROCO:6744
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6744 has been successfully added to your 
